NCT04471272

Brief Summary

The investigators intend to perform RFA therapy on HCC less than 4 cm in size using octopus electrode, double alternating unipolar high-frequency transmission mode and gradual high-frequency energy loading mode, and to find out the therapeutic results. The primary evaluation variable is the ideal technical success rate for securing a safety margin of 5 mm or more around the tumor on the CT obtained immediately after the procedure, and the secondary evaluation variable is the volume of the cauterization lesion per unit time measured on the CT obtained immediately after the procedure, The local tumor recurrence rate, survival rate and disease-free survival rate of 12 months after the procedure, the presence or absence of multiple recurrences within the same segment, the actual procedure time, and the incidence of complications associated with the procedure are examined. The performance of RFA therapy of HCC using the Octopus electrode and gradual high-frequency energy transfer mode is compared with that of the existing Octopus electrode and RFA therapy using the basic maximum high-frequency energy transfer mode using historic cohort.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 6, 2020

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 31, 2020

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 15, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2022

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
Last Updated

March 17, 2021

Status Verified

March 1, 2021

Enrollment Period

2.6 years

First QC Date

March 31, 2020

Last Update Submit

March 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Ideal technical success rate

    Secure a safety margin of 5 mm or more around the tumor on CT obtained immediately after the procedure

    Time: immediately

Secondary Outcomes (6)

  • Ablation volume

    Time: immediately

  • Local recurrence rate

    Time: 12months

  • Overall survival rate

    Time: 3years

  • Disease free survival

    Time: 3years

  • Complication rate

    Time: immediately

  • +1 more secondary outcomes

Study Arms (1)

RFA using gradual RF energy delivery mode

EXPERIMENTAL

RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.

Procedure: RFA using gradual RF energy delivery mode with Octopus electrodes

Interventions

RFA therapy is performed on HCC less than 4 cm in size using an octopus electrode, a double-shift unipolar high-frequency transmission mode, and a gradual high-frequency energy loading mode.

RFA using gradual RF energy delivery mode

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • agree to the protocol's requirements and submit a consent form
  • years old-85 years old
  • Child-Pugh Class A
  • among patients with chronic hepatitis or cirrhosis, MDCT or MRI hepatocellular carcinoma of less than 4 cm in size was suspected, and was referred to the radiology department considering clinical RFA therapy as a clinical judgment.

You may not qualify if:

  • when the number of malignant HCC is 3 or more
  • if the tumor has a maximum size of more than 4 cm
  • diffuse infiltrative HCC
  • Child-Pugh class B or C
  • If there is an invasion of liver vessels due to malignant HCC
  • severe coagulopathy
  • multiple distant metastasis
  • situations where it is very unlikely to obtain appropriate data for research purposes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Central Study Contacts

Jeong Min Lee, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: * Study population: RFA using gradual RF energy delivery mode with Octopus electrodes * Control group: Over a period of two years from 2017 to 2018, the patients who performed RFA for HCC using octopus electrodes and the maximum high-frequency energy transfer mode technique were collected. After performing propensity score matching analysis using variables of liver function values, the same number of controls are selected and set.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 31, 2020

First Posted

July 15, 2020

Study Start

January 6, 2020

Primary Completion

August 30, 2022

Study Completion

December 30, 2023

Last Updated

March 17, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations